Ticker brief

BEAM BEAM THERAPEUTICS INC

Consumer, Non-cyclical · Biotechnology

last close
$29.32
1 day
-3.8%
14 days
+9.6%
mkt cap
$3.6B
signals 14d
20
authors 14d
13
crowd 14d
+1.4σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d89% mid · 72 pctile own 1yIV/HV 1.47× (as of 2026-08-27)
Skew — 25Δ RR 30d-0.165 7 pctile own 1yputs bid vs calls (downside bid)
Net dealer OI (NDOI)+0.51 elevated5-session Δ -0.34 (as of 2026-07-16)
OI alarmquietlast alarm 2026-05-28 (z=2.7)
Next earnings2026-11-03 (proj)in 67d
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now +0.55 (−1 bearish … +1 bullish)
Who spoke13
authorgradetrader scoresignalsmean sent
@hiddensmallcapsB-0.775+0.37
@gabz_investingC+0.612+0.10
@OptionsFlowBossC·2+0.38
@Brad_E_SchulzC·2+0.10
@semodoughC-3.011+0.40
@SteveDJacobsC-1.221+0.45
@HyenukChuC+0.971+0.10
@OptionsHawkB+0.241+0.45
@PeloSwingC-0.751+0.60
@Sir_KoryC-0.111+0.35
@ArtofSpecuyckyB+0.681+0.50
@MinervaCapC-0.391+0.15
@jimmyhuliC-0.151+0.55
Recent signals20of 20 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-27@jimmyhuli+0.55Discloses multiple existing long positions across biotech and AI-related names.-3.8%
2026-08-25@MinervaCap+0.15Daily watchlist names top trades for tomorrow without explicit entry intent.-5.5%
2026-08-25@ArtofSpecuycky+0.50Presents genomics as a major decade-long investment theme and lists representative stocks.-5.5%
2026-08-25@Brad_E_Schulz+0.10Quantifies strong sector breadth and lists leading stocks.-5.5%
2026-08-25@Sir_Kory+0.35Frames gene editing as a large long-term market and compares four public platforms by maturity and risk.-5.5%
2026-08-25@PeloSwing+0.60Reports heavy buying in far-OTM BEAM calls at $40 for January 2028 and $30 for October.-5.5%
2026-08-25@Brad_E_Schulz+0.10Reports quantified intraday performance across stock categories.-5.5%
2026-08-25@hiddensmallcaps+0.00References BEAM's pipeline, but the substantive information is only in unseen media.-5.5%
2026-08-25@OptionsHawk+0.45BEAM rose 9%, its 30-day implied volatility also gained 9%, and call activity was elevated.-5.5%
2026-08-25@hiddensmallcaps+0.40H.C. Wainwright reiterates Buy and maintains an $80 target on Beam.-5.5%
2026-08-25@OptionsFlowBoss+0.55Reports bullish positioning in BEAM options.-5.5%
2026-08-23@HyenukChu+0.10Presents a genome-sector basket, but the accompanying image is needed for the underlying analysis.-1.5%
2026-08-23@SteveDJacobs+0.45Explains a stage-analysis screen where BEAM ranks stronger and IBM shows mean reversion.-1.5%
2026-08-22@hiddensmallcaps+0.45Notes a bullish higher-high pattern while BEAM rides its 200-day moving average.-1.5%
2026-08-21@gabz_investing+0.20Reports two-day gains after previously issued buy signals.-1.5%
2026-08-21@hiddensmallcaps+0.40Compares gene-editing basket valuations with IONQ to argue biotech sentiment has room to improve.-1.5%
2026-08-21@hiddensmallcaps+0.60Expects MRNA news to renew investor interest in PRME, BEAM and related biotechnology names.-1.5%
2026-08-21@OptionsFlowBoss+0.20Lists unusually high bullish options-volume multiples; later bearish remark is not assigned to named stocks.-1.5%
2026-08-20@gabz_investing+0.00Recaps hypothetical overnight returns from yesterday's signals and proposes a future experiment.+3.3%
2026-08-17@semodough+0.40BEAM plans a risto-cel BLA by year-end and a roughly 50-patient A1ATD registration study in 2H26.+8.2%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.